- Home
- LSH vs HOTH Comparison
LSH vs HOTH Comparison
Compare LSH & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSH
- HOTH
- Stock Information
- Founded
- LSH 2018
- HOTH 2017
- Country
- LSH United States
- HOTH United States
- Employees
- LSH N/A
- HOTH N/A
- Industry
- LSH
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- LSH
- HOTH Health Care
- Exchange
- LSH NYSE
- HOTH Nasdaq
- Market Cap
- LSH 7.0M
- HOTH 8.3M
- IPO Year
- LSH 2024
- HOTH 2019
- Fundamental
- Price
- LSH $0.99
- HOTH $0.95
- Analyst Decision
- LSH
- HOTH Strong Buy
- Analyst Count
- LSH 0
- HOTH 3
- Target Price
- LSH N/A
- HOTH $4.00
- AVG Volume (30 Days)
- LSH 27.0K
- HOTH 218.1K
- Earning Date
- LSH 05-16-2025
- HOTH 05-20-2025
- Dividend Yield
- LSH N/A
- HOTH N/A
- EPS Growth
- LSH N/A
- HOTH N/A
- EPS
- LSH N/A
- HOTH N/A
- Revenue
- LSH $16,927,719.00
- HOTH N/A
- Revenue This Year
- LSH N/A
- HOTH N/A
- Revenue Next Year
- LSH N/A
- HOTH N/A
- P/E Ratio
- LSH N/A
- HOTH N/A
- Revenue Growth
- LSH 2.84
- HOTH N/A
- 52 Week Low
- LSH $0.88
- HOTH $0.58
- 52 Week High
- LSH $5.37
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- LSH N/A
- HOTH 58.53
- Support Level
- LSH N/A
- HOTH $0.85
- Resistance Level
- LSH N/A
- HOTH $0.95
- Average True Range (ATR)
- LSH 0.00
- HOTH 0.06
- MACD
- LSH 0.00
- HOTH 0.02
- Stochastic Oscillator
- LSH 0.00
- HOTH 91.35
About LSH LAKESIDE HOLDING LTD
Lakeside Holding Ltd i an integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including cross-border freight consolidation and forwarding services; customs clearance services; warehousing and distribution services and U.S. domestic ground transportation services.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.